$XBI $70.14 | -0.27%
Table of Contents:
Covid Updates
$OCGN -1.8% Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXINâ„¢ (BBV152). source
Pipeline Updates
$CLBS -1.8% Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction source
$CYTK +0.2% Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress source
$IBRX -2.6% ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ. source
$NBIX +0.4% Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022. source
$DAWN +0.3% Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors. source
$ASND +1.7% Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial. source
$LMNL -11.9% Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras. source
$RAPT -6.6% RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis. source
$CBAY -5.7% CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival. source
$BHVN +0.7% US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine. source
$BHVN +0.7% Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA). source
$CMPS -4.0% COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting. source
$JAGX -1.2% Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index. source
$CNCE -8.8% Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata. source
$IMGN -0.3% ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review. source
$GLSI +4.3% Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting. source
$KALA -6.3% Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc. source
$MCRB -7.6% Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting. source
$NYMX -63.9% NYMOX Receives RTF letter from FDA.
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$CBIO +20.4% Catalyst Biosciences Sells Complement Portfolio for $60 Million.
$MIRM -1.4% Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals. source
$GLSI +4.3% Greenwich LifeSciences to Resume Stock Repurchase Program. Source
Posted by JM/FS